Generational

medical device/diabetes/biotech

[Generational @generational18]

$TMDX Schools out for summer 🎶🎵🎵 going to be interesting to see how the flights hold up for the last few weeks of the quarter

[Bridge to Life @BridgetoLifeLTD]

2026 is becoming a defining year for the organ preservation market. With FDA De Novo clearance of the VitaSmart™ HOPE System, the first hypothermic oxygenated perfusion technology cleared for liver transplantation in the U.S., Bridge to Life is now positioned at the forefront of a rapidly expanding clinical and commercial landscape.
Adoption is accelerating across major transplant centers, including Duke, University of Rochester, and Methodist Dallas, and the first U.S. OPO, which leveraged HOPE to recover a liver initially deemed unsuitable for transplant. The Bridge to HOPE randomized trial, published in “JAMA Surgery”, further strengthens the clinical and economic case for end‑ischemic HOPE in higher‑risk grafts.
International momentum is building as well, with NICE recommending routine use of liver preservation machines — including VitaSmart™ — across the NHS.
As transplantation shifts toward biologically guided, viability‑driven decision‑making, HOPE and emerging mitochondrial biomarkers like FMN represent a significant opportunity to reduce discard rates, improve outcomes, and reshape the economics of organ utilization.
Bridge to Life is well‑positioned in a market that is clearly moving toward advanced preservation and real‑time viability assessment.
Read Don Webber’s full CEO Perspective https://t.co/rxqOyAQ5Gt
#MedTech #HealthcareInnovation #OrganPreservation #MachinePerfusion #MedicalDevices #Transplantation #BridgeToLife

[Generational @generational18]

Much needed islets should be classified as organs $ELDN $NCEL @ForPlanetPluto

[Breakthrough T1D @BreakthroughT1D]

Great news! Senate Diabetes Caucus co-chairs @SenatorShaheen and @SenatorCollins have sent a letter to Acting FDA Commissioner Diamantas urging the reclassification of deceased donor islets as organs.
Momentum is building. These islets can help some people living with T1D today.

The regulatory pathway needs to catch up, and Breakthrough T1D will keep pushing until it does.

Thank you to our champions in the Senate! Use your voice: https://t.co/fsHfD6cTo5

[Generational @generational18]

Why not just transplant the patients own islets in the liver? I don’t understand the need for this pouch at all.

[Generational @generational18]

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | https://t.co/rTMrRjeqeN https://t.co/C3SuUTuvWz

[Generational @generational18]

Should she a widening eGFR gap between the tego arm and tacro arm

[Eledon Pharmaceuticals, Inc. @Eledon_Pharma]

We’re pleased to announce the $ELDN team will present results from our Phase 2 BESTOW extension trial in #KidneyTransplantation at the American Transplant Congress in Boston. For presentation details, see our press release: https://t.co/DXY9MPRkSJ @ASTSChimera @AST_info

[Generational @generational18]

@ForPlanetPluto The question is when do they get it? Will it come at their summer meeting with the FDA or will it come later in the year.

[Generational @generational18]

@Sean92295376191 Most likely senario in my book is the islets work but they don’t completely avoid immune suppression and the Manufacuring scale isn’t nearly large enough to cure everyone who wants this therapy.

[Generational @generational18]

Anyone have opinions on $IPSC vs $SANA for stem cell derived islets?

[Generational @generational18]

@Sean92295376191 And although Sana has in human data the c peptide production and dose are not near what they need to be for a cure. I think creating these islets that completely avoid immune suppression and also are at a scale large enough to cure tens of thousands of patients is a ways off

[Generational @generational18]

Of course SAB Bio is up 25% on the news. It is a better product most likely but clinically significant…not so much

[Generational @generational18]

Never really understood why someone would use these drugs. It just slows the decline in insulin production but the patients are still using insulin, it only lasts 18 months, and there are some major side effects. https://t.co/5ybsJUhW1G

[Generational @generational18]

I think to get widespread usage it would have to have very few side effects, last multiple years and keep patients from having to use injected insulin.

[Generational @generational18]

@ForPlanetPluto One patient completely off myfortic as well so completely CNI free

[Generational @generational18]

@FreddyLA7 Find an American woman Freddy to keep you warm

[Generational @generational18]

@PhilStacey_SN @NickGiannino_GT What a joke

[Ginger Vieira @GingerVieira]

Congrats to the 12th participant who is officially insulin independent in the Eledon clinical trial using Tegoprubart — an investigational therapy that works as a very targeted and relatively gentler form of immunosuppressive therapy.

All 12 participants in this groundbreaking trial are successfully producing enough insulin from the transplanted cadaver islet cells they received over the last year.

#t1d #t1dcure #diabetes #cureresearch #diabetesnerd

[Generational @generational18]

@CristinaDeReins Why is tegoprubart and tacrolimus needed at the same time? Is it just giving the xeno transplant the best chance of not being rejected?